Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Volociximab in Platinum-Resistant Ovarian or Primary Peritoneal Cancer
2007-003984-33Phase 2Terminated
- Sponsor
- Biogen
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volociximab in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), sponsored by Biogen. Primary endpoint: Objective response rate. Started Dec 2007; status: terminated.
02
Drugs
volociximab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2007-003984-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003984-33.